Home Tags SYD985

Tag: SYD985

One red Dutch tulip

Trastuzumab Duocarmazine for Treatment of HER2-Expressing Breast Cancer

Trastuzumab duocarmazine* (SYD985; Synthon) is a novel antibody-drug conjugate composed of the recombinant humanized anti-epidermal growth factor receptor 2 (HER2) monoclonal antibody trastuzumab linked,...

Trastuzumab Duocarmazine Granted U.S. FDA Fast Track Designation for Pre-treated HER2+...

The United States Food & Drug Administration (FDA) has granted Fast Track designation for The Netherlands-based Synthon Biopharmaceuticals investigational anti-HER2 antibody-drug conjugate or ADC...

Anti-HER2 ADC SYD985 to be Evaluated in Expanded Cohort of HER2+...

Dutch pharmaceutical company Synthon Biopharmaceuticals has initiated the second part of an ongoing phase I clinical trial with its investigational anti-HER2 antibody-drug conjugate or ADC,...

Initial Results from Phase I Trial with anti-HER2 ADC SYD985 Shows...

Researchers working for Dutch pharmaceutical company Synthon Biopharmaceuticals based in Nijmegen, The Netherlands, report positive initial results from the dose-escalation part of its ongoing first-in-human trial...

Preclinical Data Confirms Therapeutic Potential of SYD985 in Patients with Low...

Preclinical data of SYD985, presented by Synthon Biopharmaceutical's Gijs Verheijden during the 37th Annual San Antonio Breast Cancer Symposium (SABCS), being held at The...

FEATURED RESOURCES